CJC 1295 (No DAC) + Ipamorelin (Research Grade)

CJC-1295 (No DAC) combined with Ipamorelin is a dual-peptide formulation currently under investigation for its interaction with growth hormone–related signaling pathways. This combination is widely studied in experimental models exploring synergistic peptide activity and regulatory endocrine processes.

The absence of DAC (Drug Affinity Complex) allows for a shorter activity profile in research settings, while the combination with Ipamorelin supports targeted receptor interaction. Together, they are relevant in advanced studies focused on pulsatile signaling, pathway modulation, and systemic physiological responses.

Cellexa Labs Standard
Supplied in high-purity, lyophilized form, this peptide blend is manufactured to ensure stability, consistency, and reliability across research applications.

Key Features

• ≥99% Purity
• Dual-Peptide Formulation
• No DAC (Shorter Activity Profile)
• Lyophilized Powder Format
• Research-Grade Quality

Research Overview

CJC-1295 (No DAC) and Ipamorelin are studied for their involvement in receptor-mediated pathways associated with growth hormone signaling, endocrine regulation, and coordinated peptide activity.

Disclaimer

For research purposes only. Not for human consumption.